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ice are the most tractable and widely utilized mammalian model of disease, primarily because of their amenability to genetic engineering to probe molecular pathways. For cardiac disorders, clinically inspired mouse models of pressure overload, myocardial infarction, hormone hyper-stimulation, and cardiotoxic stress are well established and have been widely combined with genetically modified backgrounds to explore mechanisms. Another common intervention is cardiac pacing, which is clinically used to regulate heart rhythm and function. In 2006, we reported the first effort to chronically pace mice that used a custom implantable battery-powered stimulator and lead system. 1 Although effective in the short term, it often suffered battery run down and lost capture after 10 days. A second effort, reported in 2015, 2 surrounded mice in an electromagnetic field to induce current wirelessly in an implanted lead. This system, however, was limited to acute studies in sedated mice. In late 2018, Hulsmans et al 3 used a newly developed clinical miniature pacemaker (Micra; Medtronic, Minneapolis) customized with a unipolar lead to provide chronic (4-week) fixed rate pacing. This method, however, does not provide continuous monitoring, making overdrive pacing at near the sinus-rate unattractive given the risk of capture loss. In addition, the pacemaker is expensive, and though small, is 7% of the weight of an average mouse.
In addition to regulating heart rate, another use of pacing is to improve cardiac function in failing hearts with electrical conduction delay and corresponding intraventricular contractile dyssynchrony. Dyssynchrony results from early electrical activation at one region of the ventricle that is followed by late activation of the opposite region. Cardiac resynchronization therapy (CRT) offsets this by simultaneously stimulating both regions, enhancing chamber mechanics and energetic efficiency, 4, 5 and is now standard therapy in appropriate patients. 6 CRT also disproves the theory that any means of stimulating ventricular systolic function and work in a failing heart will worsen long-term outcome, as CRT improves both morbidity and mortality. 6 This aspect spawned basic research to identify cellular and molecular effects of dyssynchrony and CRT, and these revealed that CRT enhances myocyte survival, 7 β-adrenergic signaling, [8] [9] [10] mitochondrial ATP synthesis, 11 sarcomere calcium sensitivity, 12 and calcium homeostasis. [13] [14] [15] All of these findings were obtained in large mammals (mostly tachypaced dogs), 16 and adoption to mice for more mechanistic studies remains absent.
The current study aimed to develop a method for chronic pacing of the mouse atrium or ventricle with simultaneous ECG recording in conscious minimally constrained mice. Our second goal was to use the method to model cardiac dyssynchrony and resynchronization with a background of ischemic heart disease. Rather than pursue implantable stimulators, we use an externalized custom combination bipolar pacing and ECG recording lead that passes through a spring-conduit and near-frictionless electrical commutator to an external pulse generator/recorder system. We then applied the method to assess cardiac dyssynchrony and resynchronization in mice and reveal chamber, cellular, and molecular changes that are concordant with results previously only obtained in large mammals. The method and application opens up new approaches to study chronic electromechanical cardiac disease and interventions.
METHODS
All individual data and analysis will be made available to other researchers on reasonable request to the corresponding author, for the purpose of replicating the procedures. Although it is not feasible for us to provide all the specific equipment used for the chronic pacing system, all of the components except for the pacing leads are commercially available, and we will assist anyone who wishes to develop the system for their own use. Figure 1 shows components of the mouse pacemaker system. It is composed of a custom pacemaker/ECG lead ( Figure 1A , construction details in Methods and Movie I in the Data Supplement), a spring-conduit containing 4 wires ( Figure 1B ) terminating with 4-pin connectors at each end to link the externalized lead
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WHAT IS NEW?
• We present a novel method for long-term (4-week) continuous atrial and ventricular pacing in conscious mice with simultaneous ECG recording.
• Right ventricular pacing-induced cardiac dyssynchrony superimposed on mouse hearts with ischemia/reperfusion injury worsens ventricular and myocyte function, and this is improved following electromechanical resynchronization. RNA-sequencing shows broad expression heterogeneity from dyssynchrony and stress-response kinase changes induced by dyssynchrony are largely reversed by resynchronization.
• Murine cardiac dyssynchrony and resynchronization results share similarities with larger mammal and human findings, providing a translational platform to dissect molecular signaling of this and other stimulation-based heart therapies.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The chronic mouse heart pacing/recording system opens up new avenues of research into cardiac stimulation physiology and therapeutics. The dyssynchrony and resynchronization model may facilitate discoveries of new molecular targets for heart failure therapy.
( Figure 1C ) to a miniature electrical slip-ring commutator (Model SL-88-10; Dragonfly R&D, Inc, Ridgeley, WV; Figure 1D ). The latter is mounted centrally atop a standard rat-cage ( Figure 1E ), allowing the mouse to move with minimal constraint while maintaining continuous electrical contact for pacing and ECG recording. The pacing lead has a micro-pitchfork shape, with anode and cathode made from 38 gauge (0.1 mm) platinum wire. The commutator transmits up to 6 independent electrical signals while simultaneously rotating 360 o with minimal torque. The externalized pacing wires are connected to a pulse generator (SD9; Grass Instruments, Quincy, MA) and ECG-leads to a data-acquisition system (LabChart; PowerLab, ADInstruments, AU) for continuous display and signal analysis.
Pacemaker and ECG Lead Implantation
The procedure for constructing the pacing/recording lead and its implantation are provided in Methods and Movies I and II in the Data Supplement. Mice are anesthetized with isoflurane, intubated and placed on a mechanical ventilator. Anesthesia is maintained with 1.8% to 2% isoflurane. A small incision is made in the midscapular region with the mouse in a prone position and serves as the exit site for pacing/recording lead. With the mouse on its back, a small skin incision is made in the left lateral thorax. Next, the mouse is rotated to a right lateral decubitus position, and the lead tunneled subcutaneously to the skin incision in the left lateral thorax. After performing a limited left lateral thoracotomy into the second intercostal space, the pericardium is removed, right ventricle (RV) identified, and 100% platinum pacemaker electrodes pushed gently into the wall at a ≈45° angle to the mid-RV free wall. The wires are sufficiently small and firm to pass through the myocardium easily without causing any noticeable collateral tissue damage. The same procedure is used for atrial implants, but access is through the third intercostal space. Once the electrodes are implanted, 10 µL corticosteroid (triamcinolone acetonide nasal spray; Geiss, Destin & Dunn, Peachtree City, GA) is applied to the surrounding epicardium and secured with 1 µL tissue adhesive (Vetbond, 3M; St Paul, MN; ≈volume of single drop at tip of standard gel electrophoresis loading pipette). Initial capture thresholds are generally <1.5 V at 0.5 ms pulse width. The majority (75%) of thresholds remain <2.5 V with only 18% rising above 5 V within the 28-day period (Figure in the Data Supplement). The thoracotomy is closed with 6-0 prolene sutures, the mouse placed in a prone position, and the ECG electrodes tunneled subcutaneously into each upper proximal limb and sutured to the superficial muscle layer. The externalized 4-pin connector is placed within a plastic protector and secured closing the initial midscapular incision. Buprenorphine (0.1 mg/kg SC) is provided for peri and postoperative analgesia. Antibiotics were not employed. Figure 2 displays the flow chart for the study. All of the protocols were reviewed and approved by the Johns Hopkins University Institutional Animal Care and Use Committee. The study involved 144 C57Bl6/J adult mice (17-24 weeks old), of which 33 were allocated to control groups and the remainder to undergo ischemia/reperfusion (I/R) injury (60-minute proximal left anterior descending artery total constriction, followed by reperfusion) before receipt of the pacemaker. Based on prior studies, this yields a risk area of ≈55% of the left ventricular (LV) wall and infarct size of 25%. Mice surviving I/R (84%) were screened within 24 hours by echocardiography, and those with reduced fractional shortening (FS) falling between 25% to 40% (normal 57%) received pacing/recording leads 1 week later (n=70). Successful implants (87%) were then randomized to 4 pacing groups: (1) synchronous heart failure (SynHF) with 4 weeks of sinus rhythm (SynHF SR , n=14); (2) dyssynchronous HF (DysHF, n=13) with 4 weeks of RV pacing (RVP) at the lowest rate needed to assure capture; (3) SynHF with 4 weeks atrial pacing (SynHF AP , n=7) serving as a rate-matched control for DysHF; and (4) resynchronized HF (ResynHF, n=13) with 2 weeks RVP followed by 2 weeks normal sinus rhythm (NSR). We used this approach rather than biventricular stimulation because it greatly simplified the instrumentation. Importantly, the effects of CRT stem principally from its reestablishment of coordinated contractions, which is generated by restoring normal His-Purkinje excitation as with biventricular pacing. 8 Lastly, we studied nonfailing controls (NF-CON, n=11) with NSR and no lead implant, and 2 NF control groups with lead implants: NF+Lead, without pacing, and NF+RVP with RVP-induced dyssynchrony (n=11/ both). The latter groups were studied with a 2-week protocol.
Heart Failure Model and Pacing Protocol
For groups 1 to 4, acute 3-lead ECG and echocardiography studies were obtained after pacemaker implantation to assess the effects of pacing on electromechanical dyssynchrony. Mice were housed in a temperature-controlled room (27.8°C and a 12-hour light-dark cycle, 8 am-8 pm). At the end of the study, mice were anesthetized and hearts rapidly removed. Both atria and RV were dissected from the LV. The LV was then divided into 5 segments: the distal apex, septum (early activated in DysHF), lateral wall (late activated in DysHF), anterior wall (peri-infarct zone), and posterior wall (remote). Myocardium was rapidly frozen in liquid nitrogen and stored at −80°C until analyzed. In 7 studies, the LV was subjected to a myocyte isolation protocol for cell studies.
Echocardiography
Cardiac short-axis wall thickness, LV dimensions, and FS were measured by 2-dimensional echocardiography (Vevo 2100; VisualSonics, Inc, Toronto, Canada). Data were obtained before and 24 hours after I/R, 24 hours after pacemaker implantation, and at completion of the pacing protocol. In ResynHF mice, additional images were obtained after 2 weeks RVP and 1 and 7 days after return to NSR (resynchronization). Studies were performed under NSR, with ≥15-minute suspension of pacing in conscious, acclimated, manually constrained mice.
Heart Rate Analysis, Capture Verification, Threshold Testing, and Pacemaker Settings
Electrocardiograms were continuously recorded throughout the study. In 10 SynHF SR , the native heart rate was analyzed daily over four 10-s segments every 6 hours and then averaged over the 4-week study. In mice receiving pacing, the percent of captured heartbeats was calculated from the ratio of pacedbeats to total heart-beats during similar 10-s segments. The pacemaker capture threshold at 0.5 and 2.5 ms pulse duration was checked daily and the stimulator output set to twice threshold. Mice with an early capture threshold rise (>5 V at 2.5 ms pulse width in the first 3 weeks, Figure in the Data Supplement) were removed from the study. Pacing rate was set to 720 beats per min during the first week and 650 beats per minutes thereafter. To assure capture, small adjustments in pacing rate were made daily based on individual mouse rates.
Cardiomyocyte Function Studies
Myocytes were isolated from NF-CON, SynHF SR , DysHF, and ResynHF groups (n=18-50 cells, mean 37 cells per group from 7 hearts), using retrograde perfusion of the isolated heart with zero calcium buffer and collagenase. 17 The septum was then cut out, placed in buffer within a shallow dish, and myocytes gently disaggregated. We focused on this territory as it was less impacted by scar at and around the myocardial infarct, and so provided a greater yield of viable cells. Myocyte sarcomere shortening and whole-cell calcium transients were measured using 1.0 mmol/L Ca 2+ in buffer solution, 17 at a stimulation rate of 0.5 Hz and 37°C, before and after incubation with isoproterenol (10 nmol/L). Data were obtained using the IonOptix system (MyoCam, IonOptix, Milton, MA) on an inverted microscope (Nikon Eclipse TE2000).
Protein Kinase Phosphorylation Assay
To evaluate posttranslational modification/activation of multiple signaling kinases associated with growth, mitogen activation, survival and metabolic signaling, and other pathways, we used a kinase-activity array (Proteome Profiler Array, ARY003B; R&D Systems, Minneapolis, MN) which simultaneously assesses phosphorylation of a panel of 43 relevant kinases, using tissue extract from the LV lateral wall (the region of highest wall stress in a dyssynchronous heart) 7,9 and following manufacturer instructions.
RNAseq Analysis
To assess differential gene expression between early contracting (septum) and late-contracting (lateral) wall in HF-LV left ventricles with and without RVP-induced dyssynchrony, RNA was extracted from myocardial samples using Qiagen RNeasy Mini kit and used for cDNA library synthesis using Illumina TruSeq RNA Library Prep kit v2 following manufacturer's instructions. Libraries were sequenced on an Illumina HiSeq 4000 machine that produced 396 million 100-bp single-end reads (W. M. Keck Biotechnology Center at University of Illinois at Urbana-Champaign). RNA-sequencing reads were trimmed and mapped to the Ensembl mouse reference genome (mm10) using HISAT2 version 2.0.5 (http://ccb.jhu.edu/ software/hisat2/index.shtml). Transcript counts were quantified using RSEM v1.3.0 with default parameters. 18 Differential expression analysis was performed using R package DESeq2 v1.18.1. 19 Pathway analysis of differentially expressed genes with adjusted P<0.05 (false discovery rate <5%) used the Kyoto Encyclopedia of Genes and Genomes database and R package KEGG.db v3.2.3 (http://bioconductor.org/packages/ release/data/annotation/html/KEGG.db.html).
Statistical Analysis
Data are presented as mean±SD unless specifically indicated. Between-group comparisons were generally performed using 1-way ANOVA, with post hoc multiple pairwise comparisons testing by Tukey test. If indicated, a nonparametric KruskalWallis test with Dunn test for multiple comparisons was used. Time-course data were analyzed by repeated measures ANOVA. Individual tests are noted in each figure legend, as is sample size. Statistical analysis was performed using GraphPad Prism7 (GraphPad Software, La Jolla, CA). P values are provided in each figure, and P<0.05 considered statistically significant.
RESULTS
Cardiac Pacing System in Mice With I/R Injury
Of the 61 mice subjected to the pacing protocol, 6 died before completing the full protocol. An additional 8
were withdrawn because of a high pacing-threshold with loss of ventricular or atrial capture (Figure 2 ). Intrinsic heart rate was 517 beats per minute (25%-75% quartiles: 434-598, from 952 recordings) in the SynHF SR group and the pacing rate was 650 bpm (650-720, from 281 recordings). This rate was similar among the different pacing groups, and myocardial capture was achieved in 92±5.7% of paced beats for atrial and ventricular pacing.
Electromechanical Dyssynchrony and Resynchronization in Mice
Representative ECG tracings and group data for QRS-duration and electrical axis are provided in Figure 3A and 3B. QRS-duration and electrical axis were unaltered between normal sinus NF-CON and I/R-HF mice with normal sinus or atrial pacing (SynHF SR , SynHF AP ). QRS widened by 50%, and axis shifted on average −130° in DysHF versus the other groups (both P<0.0001) . Wall motion dyssyn- chrony indexed by the time delay between septumto-posterior wall motion or anterior-posterior wall motion 20 ( Figures 3C and 3D ) only increased in the DysHF (P≤0.002).
Individual and group echocardiographic results are displayed in Figure 4 , with all measurements obtained at NSR, with pacing temporarily suspended. Following I/R, FS declined, and LV end-systolic diameter increased similarly among the different pacing groups ( Figure 4A and 4B) . In SynHF SR and SynHF AP hearts, there was minimal further change 4 weeks later, and data for both groups were similar. However, FS declined further in DysHF (from 36±6 to 24±6%), and LV end-systolic diameter increased (2.4±0.4 to 3.1±0.6 mm), becoming significantly different than that of the other groups (P≤0.007, individual P values in legend). LV function in ResynHF was similar to both SynHF groups, reversing the changes in DysHF. In ResynHF, FS declined from 36.2±2.8 to 28.6±1.8 (P=0.004), and left ventricular end-systolic diameter rose (2.1±0.2 to 2.8±0.1) after only 2 weeks of RVP, values similar to those after 4 weeks RVP in DysHF. These were unaltered 1 day after stopping pacing, confirming they were intrinsic to the heart and did not require active RVP. However, after 1 week of restored synchronous contraction, LV function improved to post-I/R levels, and this persisted thereafter. We also tested the impact of RV-pacing dyssynchrony on LV function in normal hearts ( Figure 4D ), finding minimal effects after 2 weeks unlike the response in the 2-week RVP phase of ResynHF mice ( Figure 4C ). This supports the importance of underlying LV disease to observe meaningful pathobiology from dyssynchrony.
Isolated Myocyte Studies
Individual example time-tracings of myocyte sarcomere shortening and calcium transients at baseline (control) and during isoproterenol stimulation from the various experimental groups are shown in Figure 5A . Summary data are provided in Figures 5B  and 5C . Despite the variance among cells, mean sarcomere shortening in the basal state was substantially lower in all HF groups versus control, and DysHF was significantly below all the other pacing groups (P=0.001 versus ResynHF; P<0.0001 versus NF-CON and SynHF SR , Tukey test, 1-way ANOVA). Isoproterenol-stimulated shortening maintained these disparities. DysHF peak calcium transients were significantly reduced both at rest and on isoproterenol stimulation compared with NF-CON and SynHF SR , but they did not differ from peak transients in ResynHF. Thus, restoring synchrony enhanced rest and isoproterenolstimulated shortening, though peak calcium transients remained depressed.
RNAseq Analysis-Regional Gene Expression Variability
We next tested the extent to which myocardial I/R injury induced regional heterogeneity of gene expres- Figure 6 . RV pacing-induced dyssynchrony in post-ischemia/reperfusion (I/R) mouse heart markedly augments regional gene expression differences between lateral and septal wall. Volcano plots of heterogeneous gene expression comparing lateral to septal wall in hearts after I/R injury with or without superimposition of sustained right ventricular pacing (RVP)-induced dyssynchrony. y axis shows −log of P value and data are shown accepting a 10% false discovery rate. There is very little heterogeneity in the post-myocardial infarction heart, but this is markedly increased after 4 wk of RVP. This remains true even if a more stringent false discovery rate (1%-5%) is used. The Kyoto Encyclopedia of Genes and Genomes analysis reveals pathways that are significantly disparate between sides of the chamber, based on the number of genes modified within each pathway. Results for up vs downregulated genes are listed below the figure; adjusted P value (adj P value; Q value, with false discovery rate <0.05). ECM indicates extracellular matrix; LV, left ventricular; pcnt, percent; PPAR, peroxisome proliferator-activated receptor; TCA, tricarboxylic acid cycle; and TGF, transforming growth factor.
sion itself (comparing noninfarcted lateral wall and septum) and if this was altered by superimposition of RVP-induced dyssynchrony. Figure 6 displays RNAsequencing data as volcano plots of genes with significant expression disparities between septal and lateral wall (P<0.05, −log(p)>1.3). The results show that despite I/R injury, synchronously contracting hearts (Syn-HF SR ) displayed only 62 genes with regional expression disparity between regions. However, with dyssynchrony, this number increased to 804 genes (Tables I  and II in the Data Supplement). Kyoto Encyclopedia of Genes and Genomes pathway analysis of differentially expressed genes found many upregulated in the lateral versus septal wall were associated with energetics and metabolism, whereas relative downregulated genes were predominantly within cytoskeletal and matrix-signaling pathways.
Regional Disparity in Protein Kinase Activation
DysHF generates both global molecular changes that impact cell myocyte behavior (eg, depressed adrenergic signaling 9 ) and regional differences in kinase activation.
7,21 Figure 7 shows results of the kinase-phosphorylation assay, showing all modified proteins in lateral wall myocardial extracts from DysHF versus SynHF SR . These include MAP (mitogen-activated protein) kinases p38, ERK1/2 (extracellular regulated kinase), and JNK (c-Jun N-terminal kinase), MSK1 (mitogen stress-activated protein kinase 1) and its downstream target CREB (cyclic AMP response element binding protein), Lyn (tyrosine protein kinase), AMP-stimulated kinase α1-subunit, and HSP27 (heat shock protein 27). Phosphorylation of GSK-3β (glycogen synthase kinase-3 beta) also increased (kinase is thereby inhibited), consistent with prior findings in dyssynchronous failing canine ventricles. 7 These changes were significantly reversed with resynchronization in all but 2 proteins (CREB and Lyn).
DISCUSSION
We developed a method to chronically and continuously stimulate and concomitantly record electrical activity of the heart in conscious and minimally constrained mice. This was then applied to model LV disease with electromechanical dyssynchrony or resynchronization. The new technology is the first to enable both pacing and continuous electrophysiological monitoring in conscious mice and has a low (13%) combined procedural failure or mortality rate. It utilizes custom leads and commercially available electronic components allowing for scalability without excessive cost. By using an external pulse generator, a broad range of stimulation protocols are feasible all the while providing simultaneous pacing and recording.
There are several methodological differences between the recent mouse pacing study from Hulsmans et al 3 and our approach. The implantable pacemaker used in their study was first clinically tested in 2013, and their modified version enables chronic fixed pacing at high rates. However, it is not amenable to more complex pacing protocols, whereas ours is flexible as the stimulator is externalized. Although the miniature pacemaker is small and light for humans, it is still nearly 2 grams, representing ≈7% of the weight of a typical mouse, or 5.2 kg for a 75 kg human (weight of ≈2.5 standard bags of flour). By contrast, we require implantation of just a light pacing lead. Admittedly, our lead is not currently commercially available and requires some training to make, but we have achieved this with multiple individuals, and Movie II in the Data Supplement is intended to make the process clear. A potential disadvantage of externalizing the lead is morbidity from infection, though we found this to be very rare. Each component of the externalized conduits is designed to facilitate freedom of movement while still protecting the wires from being chewed by the mouse. Lastly, the implantable pacemaker requires a unit/mouse, and based on their clinical cost of $7000-$10 000 US, scaling up could be expensive.
The results of the present dyssynchrony and resynchronization model are the first such analysis in the mouse and first to assess cellular and molecular modifications from either intervention when superimposed on a model of preexisting ischemic heart disease. Virtually all prior data derives from a canine model of tachypacing induced HF, 16 where the evolution of failure and pacing-dyssynchrony or CRT effects were coupled. The data reveal striking similarities at many levels to what is reported in the dog, 7, 8, 22 and in some limited studies in humans, 23 revealing the mouse to be a viable model system to explore this pathophysiology. This was not a foregone conclusion, given the mouse heart is small so there is less distance to be traveled from early to late stimulated muscle at myocardial conduction velocities similar to those found in humans. 24 Hulsmans et al 3 subjected mice to RV-apex or atrial tachypacing (at 1200 beats per minute), and the former but not latter resulted in LV dysfunction. However, 1:2 atrial-paced beats induced ventricular excitation, so the effective rate was ≈600 bpm. Although this suggests LV disease from tachypacing occurs in mice as in larger mammals, it might also reflect the impact of dyssynchrony from RVP. Indeed, we show RVP at ≈600 beats per minute also worsens LV and myocyte function so long as underlying cardiac disease is present, whereas atrial pacing at the same rate does not. The new mouse model also differs from prior work on cardiac dyssynchrony and CRT performed mostly in the dog that used tachypacing as a background to generate HF. That the results are similar is reassuring and opens up new ways to study this behavior.
The present study did not aim to recapitulate the nearly 15 years of work conducted in the canine model which revealed how CRT modifies adrenergic and cell survival signaling, gene expression heterogeneity, and myocyte function and calcium homeostasis. Rather, we focused on generating some key new data sets, specifically as this was performed in an ischemic disease model, and the RNAseq results provide fodder for future research. The activation of MAP (mitogen-activated protein) kinase activity by dyssynchrony and its resolution by resynchronization not only recapitulates several prior canine findings 7, 21 but also adds many more pathways to the affected list. The finding that GSK-3β inhibition (eg, increased S9 phosphorylation) 7 is observed in mouse dyssynchrony as in the canine heart is interesting, as this was previously shown in dogs to contribute to myofilament dysfunction and be reversed by CRT. 12, 25 This may in part explain the improved myocyte function in ResynHF despite persisting depressed calcium transients. Future work utilizing genetically modified mice to dissect out the role of specific protein changes can now be performed.
There are some limitations to our study. We did not sense or inhibit pacing based on intrinsic electrical stimulation, but paced continuously; however, this could be modified by using a more sophisticated external pulsestimulator. We required pacing rates 25% above normal sinus to assure >93% capture. Although this could introduce a rate effect, mean heart rate was identical for SynHF AP and DysHF groups. Moreover, though heart rate was lower at NSR than with pacing, both SynHF AP and SynHF NS displayed similar results. The ResynHF model did not employ biventricular pacing, as is used with CRT, though resynchronization of contraction was similar. Although I/R itself induces regional changes in myocardial biology, it did not induce significant dyssynchrony by image analysis and was common to all the pacing models. Despite this, we observed differences at chamber, cellular, and molecular levels from pacing-induced dyssynchrony. Furthermore, reversibility of the RV-pacing related abnormalities on restoring normal conduction indicates that the pathobiology related to superimposed dyssynchrony and not the preexisting I/R injury.
In summary, the current study presents a detailed method for chronic mouse pacing and applies it to generate a model of dyssynchrony and resynchronization. The full utility of this platform for dissecting critical molecular signaling relevant to this or other electromechanical interventions remains to be explored. The distinction between altering myocardial biology by pharmaceuticals, biologicals, or devices, such as pacemakers, is becoming increasingly blurred. More and more evidence shows electromechanical stimulation that alters conduction and associated ventricular contraction is also a potent tool to vary underlying cell structure and function. 26 The present methodology provides a new means to employ this in mice that should facilitate future mechanistic studies of these interactions. 
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